Abstract
Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.
Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin
CNS & Neurological Disorders - Drug Targets
Title: GABAergic Drugs for the Treatment of Migraine
Volume: 6 Issue: 4
Author(s): Anja Puppe and Volker Limmroth
Affiliation:
Keywords: GABA transaminase, Topiramate, Valproic acid, Gabapentin, pregabalin
Abstract: Within the last decades significant progress has been made in the understanding of the underlying pathophysiological mechanisms of migraine. There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system. The development and use of drugs targeting ion-channels and subsequently reducing cortical excitability appears as a promising avenue for both the acute treatment of migraine and migraine prevention. This review summarizes the current knowledge and evidence for GABAergic drugs in the treatment of migraine.
Export Options
About this article
Cite this article as:
Anja Puppe and Volker Limmroth , GABAergic Drugs for the Treatment of Migraine, CNS & Neurological Disorders - Drug Targets 2007; 6 (4) . https://dx.doi.org/10.2174/187152707781387305
DOI https://dx.doi.org/10.2174/187152707781387305 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Benzimidazole Derivatives as Centerally Acting Agents
Current Drug Therapy Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology Clozapine Safety, 35 Years Later
Current Drug Safety Nutraceuticals in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Quality of Life of Children with Cerebral Palsy: A Cross-Sectional KIDSCREEN study in the Southern part of the Netherlands
CNS & Neurological Disorders - Drug Targets Anticonvulsant Effect of the Essential Oil and Methanolic Extracts of <i>Zataria multiflora</i> Boiss
Central Nervous System Agents in Medicinal Chemistry Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Activators and Inhibitors of the Ion Channel of the NMDA Receptor
Current Drug Targets Possible Protecting Role of TNF-α in Kainic Acid-induced Neurotoxicity Via Down-Regulation of NFκB Signaling Pathway
Current Alzheimer Research FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals How Accurate is Subjective Reporting of Childhood Sleep Patterns? A Review of the Literature and Implications for Practice
Current Pediatric Reviews Synthesis, Molecular Docking and Evaluation of 3-{4-[2-amino-4-(substitutedphenyl)-2H-[1, 3] oxazin/thiazin-6-yl} 2-phenyl-3H-quinazolin-4-one Derivatives for their Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Ultrasonic Assisted Synthesis, Biological Evaluation, and Molecular Docking of Chalcone-based 1,5-benzodiazepine as Potential Anticonvulsant Agents
Current Enzyme Inhibition